Drug Profile
Research programme: encapsulated skin cancer therapeutics - Aphios
Alternative Names: APH-0201; Betulinic acid nanosomes/nanospheres - Aphios; Dermos; Nanosomal paclitaxel - Aphios; Nanosome/nanosphere skin cancer therapeutics - AphiosLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Lipoproteins; Triterpenes
- Mechanism of Action Apoprotein stimulants; Caspase stimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Malignant melanoma; Skin cancer
Highest Development Phases
- No development reported Malignant melanoma; Skin cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Topical, Liposomal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-cancer in USA (Topical, Liposomal)
- 17 Oct 2014 Preclinical development in Malignant melanoma is ongoing in the US